Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies

Annals of Clinical and Translational Neurology

Volumn 3, Issue 10, 2016, Pages 769-780

  Park, Hye Jin ^a   Lee, Kang Woo ^a,f   Park, Eun S ^a,g   Oh, Stephanie ^a   Yan, Run ^a   Zhang, Jie ^a   Beach, Thomas G ^b   Adler, Charles H ^c   Voronkov, Michael ^d   Braithwaite, Steven P ^d,h   Stock, Jeffry B ^d,e   Mouradian, M Maral ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d Signum Biosciences Inc   (United States)

^e PRINCETON UNIVERSITY   (United States)

^f Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h Alkahest Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; LEUCINE CARBOXYL METHYLTRANSFERASE; LEUCINE RICH REPEAT KINASE 2; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN CARBOXYL METHYLTRANSFERASE; PROTEIN PHOSPHATASE METHYLESTERASE; UNCLASSIFIED DRUG;

AGED; ALPHA SYNUCLEINOPATHY; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMETHYLATION; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTAL CORTEX; GENE MUTATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; POSTHUMOUS CARE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METHYLATION; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY;

EID: 85024866567     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.337     Document Type: Article

References (64)

1. Strack S, Westphal RS, Colbran RJ, et al. Protein serine/threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments. Brain Res Mol Brain Res 1997;49:15–28.
2. Strack S, Zaucha JA, Ebner FF, et al. Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits. J Comp Neurol 1998;392:515–527.
3. Bryant JC, Westphal RS, Wadzinski BE. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem J 1999;339(Pt 2):241–246.
4. Tolstykh T, Lee J, Vafai S, Stock JB. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J 2000;19:5682–5691.
5. Wu J, Tolstykh T, Lee J, et al. Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J 2000;19:5672–5681.
6. Lee J, Chen Y, Tolstykh T, Stock J. A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc Natl Acad Sci U S A 1996;93:6043–6047.
7. Lee J, Stock J. Protein phosphatase 2A catalytic subunit is methyl-esterified at its carboxyl terminus by a novel methyltransferase. J Biol Chem 1993;268:19192–19195.
8. Ogris E, Du X, Nelson KC, et al. A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J Biol Chem 1999;274:14382–14391.
9. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839–840.
10. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160–164.
11. Neumann M, Kahle PJ, Giasson BI, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002;110:1429–1439.
12. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281:29739–29752.
13. Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci 2011;31:6963–6971.
14. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657–663.
15. Gong CX, Lidsky T, Wegiel J, et al. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 2000;275:5535–5544.
16. Wu J, Lou H, Alerte TN, et al. Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience 2012;207:288–297.
17. Sontag E, Hladik C, Montgomery L, et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 2004;63:1080–1091.
18. Sontag E, Luangpirom A, Hladik C, et al. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 2004;63:287–301.
19. Basurto-Islas G, Blanchard J, Tung YC, et al. Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease. Neurobiol Aging 2014;35:2701–2712.
20. Beach TG, Adler CH, Sue LI, et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 2015;35:354–389.
21. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613–634.
22. Iacono D, Geraci-Erck M, Rabin ML, et al. Parkinson disease and incidental Lewy body disease: Just a question of time? Neurology 2015;85:1670–1679.
23. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479–486.
24. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
25. Wei H, Ashby DG, Moreno CS, et al. Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits Cdc55p and Rts1p. J Biol Chem 2001;276:1570–1577.
26. Sontag E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal 2001;13:7–16.
27. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell 2009;139:468–484.
28. Sangodkar J, Farrington C, McClinch K, et al. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. FEBS J 2016; 283:1004–1024.
29. Ikeuchi T, Kakita A, Shiga A, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol 2008;65:514–519.
30. Vafai SB, Stock JB. Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. FEBS Lett 2002;518:1–4.
31. Sontag E, Nunbhakdi-Craig V, Sontag JM, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 2007;27:2751–2759.
32. Obeid R, Schlundt J, Umanskaya N, et al. Folate is related to phosphorylated neurofilament-H and P-tau (Ser396) in rat brain. J Neurochem 2011;117:1047–1054.
33. Gueant JL, Caillerez-Fofou M, Battaglia-Hsu S, et al. Molecular and cellular effects of vitamin B12 in brain, myocardium and liver through its role as co-factor of methionine synthase. Biochimie 2013;95:1033–1040.
34. Sontag JM, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer's disease. Front Mol Neurosci 2014;7:16.
35. Kaut O, Schmitt I, Wullner U. Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 2012;13:87–91.
36. Feng Y, Jankovic J, Wu YC. Epigenetic mechanisms in Parkinson's disease. J Neurol Sci 2015;349:3–9.
37. Pihlstrom L, Berge V, Rengmark A, Toft M. Parkinson's disease correlates with promoter methylation in the alpha-synuclein gene. Mov Disord 2015;30:577–580.
38. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886–891.
39. Bottiglieri T, Arning E, Wasek B, et al. Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain. J Neurosci 2012;32:9173–9181.
40. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013;3:461–491.
41. Mao P. Oxidative Stress and Its Clinical Applications in Dementia. J Neurodegener Dis. 2013;2013:319898.
42. Rao RK, Clayton LW. Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. Biochem Biophys Res Commun 2002;293:610–616.
43. Foley TD, Melideo SL, Healey AE, et al. Phenylarsine oxide binding reveals redox-active and potential regulatory vicinal thiols on the catalytic subunit of protein phosphatase 2A. Neurochem Res 2011;36:232–240.
44. Stanevich V, Jiang L, Satyshur KA, et al. The structural basis for tight control of PP2A methylation and function by LCMT-1. Mol Cell 2011;41:331–342.
45. Ishizawa T, Mattila P, Davies P, et al. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003;62:389–397.
46. Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002;320:146–150.
47. Perfeito R, Lazaro DF, Outeiro TF, Rego AC. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells. Mol Cell Neurosci 2014;62:51–59.
48. Khandelwal PJ, Dumanis SB, Feng LR, et al. Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010;5:47.
49. Cho MH, Kim DH, Choi JE, et al. Increased phosphorylation of dynamin-related protein 1 and mitochondrial fission in okadaic acid-treated neurons. Brain Res 2012;1454:100–110.
50. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651–1661.
51. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012;72:455–463.
52. Liu G, Chen M, Mi N, et al. Increased oligomerization and phosphorylation of alpha-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. Neurobiol Aging 2015;36:2649–2659.
53. Du TT, Wang L, Duan CL, et al. GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy 2015;11:1803–1820.
54. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A 1999;96:4438–4442.
55. Hartley D, Cooper GM. Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem 2002;85:304–314.
56. Perez-Revuelta BI, Hettich MM, Ciociaro A, et al. Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis 2014;5:e1209.
57. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993;268:15523–15530.
58. Chalfant CE, Kishikawa K, Mumby MC, et al. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 1999;274:20313–20317.
59. Gong CX, Shaikh S, Wang JZ, et al. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 1995;65:732–738.
60. Sontag E, Nunbhakdi-Craig V, Lee G, et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 1999;274:25490–25498.
61. Nicholls RE, Sontag JM, Zhang H, et al. PP2A methylation controls sensitivity and resistance to beta-amyloid-induced cognitive and electrophysiological impairments. Proc Natl Acad Sci U S A 2016; 113:3347–3352.
62. Sontag JM, Nunbhakdi-Craig V, Mitterhuber M, et al. Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells. J Neurochem 2010;115:1455–1465.
63. Corcoran NM, Martin D, Hutter-Paier B, et al. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci 2010;17:1025–1033.
64. van Eersel J, Ke YD, Liu X, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A. 2010;107:13888–13893.